← All trials
NCT04817215
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2021
- Primary completion
- Apr 30, 2022
- Completion date
- Jul 31, 2022
- First posted
- Mar 26, 2021
- Last posted
- Mar 26, 2021
- Enrollment
- 608
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- King Hamad UniversityLead sponsor
- King Hamad UniversityOverall official - principal investigator
- Oramed Pharmaceutical Inc.Collaborator
- Royal College of Surgeons, IrelandCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.